Nuclear factor one transcription factors as epigenetic regulators in cancer

International Journal of Cancer

Volumn 140, Issue 12, 2017, Pages 2634-2641

  Fane, Mitchell ^a,b   Harris, Lachlan ^a   Smith, Aaron G ^a,b   Piper, Michael ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM12 PROTEIN; HISTONE H3; NUCLEAR FACTOR ONE TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ISOPROTEIN; NUCLEAR FACTOR I;

CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; DNA REPLICATION; EPIGENETICS; GENE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; MALIGNANT NEOPLASM; METASTASIS; METHYLATION; NFIB GENE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SMALL CELL LUNG CANCER; TUMOR GROWTH; UPREGULATION; CANCER STEM CELL; DISEASE COURSE; GENETIC EPIGENESIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; TUMOR MICROENVIRONMENT;

DISEASE PROGRESSION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; NFI TRANSCRIPTION FACTORS; PROTEIN ISOFORMS; TUMOR MICROENVIRONMENT;

EID: 85013042388     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30603     Document Type: Review

References (100)

1. Bird A, Perceptions of epigenetics. Nature 2007;447:396–8.
2. Waddington CH, The epigenotype, 1942. Int J Epidemiol 2012;41:10–3.
3. Felsenfeld G, A brief history of epigenetics. Cold Spring Harb Perspect Biol 2014;6.
4. Dawson MA, Kouzarides T, Cancer epigenetics: from mechanism to therapy. Cell 2012;150:12–27.
5. Feinberg AP, Tycko B, The history of cancer epigenetics. Nat Rev Cancer 2004;4:143–53.
6. Maegawa S, Gough SM, Watanabe-Okochi N, et al. Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res 2014;24:580–591.
7. Niwa T, Ushijima T, Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis. Adv Genet 2010;71:41–56.
8. Liu F, Killian JK, Yang M, et al. Epigenomic alterations and gene expression profiles in respiratory epithelia exposed to cigarette smoke condensate. Oncogene 2010;29:3650–64.
9. Marusyk A, Almendro V, Polyak K, Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323–34.
10. Hanahan D, Weinberg RA, Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
11. Greaves M, Maley CC, Clonal evolution in cancer. Nature 2012;481:306–13.
12. Easwaran H, Tsai HC, Baylin SB, Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 2014;54:716–27.
13. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69–80.
14. Abbott DE, Bailey CM, Postovit LM, et al. The epigenetic influence of tumor and embryonic microenvironments: how different are they? Cancer Microenviron 2008;1:13–21.
15. Dawood S, Austin L, Cristofanilli M, Cancer stem cells: implications for cancer therapy. Oncology (Williston Park) 2014;28:1101–7, 10.
16. Friedmann-Morvinski D, Verma IM, Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep 2014;15:244–53.
17. Voss TC, Hager GL, Dynamic regulation of transcriptional states by chromatin and transcription factors. Nat Rev Genet 2014;15:69–81.
18. Zhu J, Adli M, Zou JY, et al. Genome-wide chromatin state transitions associated with developmental and environmental cues. Cell 2013;152:642–54.
19. Suzuki HI, Katsura A, Matsuyama H, et al. MicroRNA regulons in tumor microenvironment. Oncogene 2015;34:3085–94.
20. Li X, Wu Z, Fu X, et al. A microRNA component of the neoplastic microenvironment: microregulators with far-reaching impact. Biomed Res Int 2013;2013:762183.
21. Chen B, Li H, Zeng X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med 2012;10:228.
22. Kulshreshtha R, Ferracin M, Wojcik SE, et al. A microRNA signature of hypoxia. Mol Cell Biol 2007;27:1859–67.
23. McGranahan N, Swanton C, Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015;27:15–26.
24. Fisher R, Pusztai L, Swanton C, Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013;108:479–85.
25. Somasundaram R, Villanueva J, Herlyn M, Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol 2012;65:335–59.
26. Rupp RA, Kruse U, Multhaup G, et al. Chicken NFI/TGGCA proteins are encoded by at least three independent genes: NFI-A, NFI-B and NFI-C with homologues in mammalian genomes. Nucleic Acids Res 1990;18:2607–16.
27. Kruse U, Qian F, Sippel AE, Identification of a fourth nuclear factor I gene in chicken by cDNA cloning: NFI-X. Nucleic Acids Res 1991;19:6641.
28. Piper M, Barry G, Hawkins J, et al. NFIA controls telencephalic progenitor cell differentiation through repression of the Notch effector Hes1. J Neurosci 2010;30:9127–39.
29. Heng YH, McLeay RC, Harvey TJ, et al. NFIX regulates neural progenitor cell differentiation during hippocampal morphogenesis. Cereb Cortex 2014;24:261–79.
30. Betancourt J, Katzman S, Chen B, Nuclear factor one B regulates neural stem cell differentiation and axonal projection of corticofugal neurons. J Comp Neurol 2014;522:6–35.
31. Steele-Perkins G, Plachez C, Butz KG, et al. The transcription factor gene Nfib is essential for both lung maturation and brain development. Mol Cell Biol 2005;25:685–98.
32. Lajoie M, Hsu YC, Gronostajski RM, et al. An overlapping set of genes is regulated by both NFIB and the glucocorticoid receptor during lung maturation. BMC Genomics 2014;15:231.
33. Messina G, Biressi S, Monteverde S, et al. Nfix regulates fetal-specific transcription in developing skeletal muscle. Cell 2010;140:554–66.
34. Biressi S, Molinaro M, Cossu G, Cellular heterogeneity during vertebrate skeletal muscle development. Dev Biol 2007;308:281–93.
35. Rossi G, Antonini S, Bonfanti C, et al. Nfix regulates temporal progression of muscle regeneration through modulation of myostatin expression. Cell Rep 2016;14:2238–49.
36. Holmfeldt P, Pardieck J, Saulsberry AC, et al. Nfix is a novel regulator of murine hematopoietic stem and progenitor cell survival. Blood 2013;122:2987–96.
37. Martynoga B, Mateo JL, Zhou B, et al. Epigenomic enhancer annotation reveals a key role for NFIX in neural stem cell quiescence. Genes Dev 2013;27:1769–86.
38. Chang CY, Pasolli HA, Giannopoulou EG, et al. NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche. Nature 2013;495:98–102.
39. Denny SK, Yang D, Chuang CH, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. Cell 2016;166:328–42.
40. Gronostajski RM, Site-specific DNA binding of nuclear factor I: effect of the spacer region. Nucleic Acids Res 1987;15:5545–59.
41. Gronostajski RM, Knox J, Berry D, et al. Stimulation of transcription in vitro by binding sites for nuclear factor I. Nucleic Acids Res 1988;16:2087–98.
42. Meisterernst M, Gander I, Rogge L, et al. A quantitative analysis of nuclear factor I/DNA interactions. Nucleic Acids Res 1988;16:4419–35.
43. Pjanic M, Schmid CD, Gaussin A, et al. Nuclear factor I genomic binding associates with chromatin boundaries. BMC Genomics 2013;14:99.
44. Pjanic M, Pjanic P, Schmid C, et al. Nuclear factor I revealed as family of promoter binding transcription activators. BMC Genomics 2011;12:181.
45. Santoro C, Mermod N, Andrews PC, et al. A family of human CCAAT-box-binding proteins active in transcription and DNA replication: cloning and expression of multiple cDNAs. Nature 1988;334:218–24.
46. Dusserre Y, Mermod N, Purified cofactors and histone H1 mediate transcriptional regulation by CTF/NF-I. Mol Cell Biol 1992;12:5228–37.
47. Alevizopoulos A, Dusserre Y, TsaiPflugfelder M, et al. A proline-rich TGF-beta-responsive transcriptional activator interacts with histone H3. Genes Dev 1995;9:3051–66.
48. Li R, Stimulation of DNA replication in Saccharomyces cerevisiae by a glutamine- and proline-rich transcriptional activation domain. J Biol Chem 1999;274:30310–4.
49. Erkine AM, Gross DS, Dynamic chromatin alterations triggered by natural and synthetic activation domains. J Biol Chem 2003;278:7755–64.
50. Muller K, Mermod N, The histone-interacting domain of nuclear factor I activates simian virus 40 DNA replication in vivo. J Biol Chem 2000;275:1645–50.
51. Ferrari S, Simmen KC, Dusserre Y, et al. Chromatin domain boundaries delimited by a histone-binding protein in yeast. J Biol Chem 2004;279:55520–30.
52. Pankiewicz R, Karlen Y, Imhof MO, et al. Reversal of the silencing of tetracycline-controlled genes requires the coordinate action of distinctly acting transcription factors. J Gene Med 2005;7:117–32.
53. Esnault G, Majocchi S, Martinet D, et al. Transcription factor CTF1 acts as a chromatin domain boundary that shields human telomeric genes from silencing. Mol Cell Biol 2009;29:2409–18.
54. Chikhirzhina GI, Al'-Shekhadat RI, Chikhirzhina EV, [Transcription factors of the nuclear factor 1 (NF1) family. Role in chromatin remodelation]. Mol Biol (Mosk) 2008;42:388–404.
55. Chavez S, Beato M, Nucleosome-mediated synergism between transcription factors on the mouse mammary tumor virus promoter. Proc Natl Acad Sci USA 1997;94:2885–90.
56. Hebbar PB, Archer TK, Nuclear factor 1 is required for both hormone-dependent chromatin remodeling and transcriptional activation of the mouse mammary tumor virus promoter. Mol Cell Biol 2003;23:887–98.
57. Belikov S, Astrand C, Holmqvist PH, et al. Chromatin-mediated restriction of nuclear factor 1/CTF binding in a repressed and hormone-activated promoter in vivo. Mol Cell Biol 2004;24:3036–47.
58. Belikov S, Holmqvist PH, Astrand C, et al. Nuclear factor 1 and octamer transcription factor 1 binding preset the chromatin structure of the mouse mammary tumor virus promoter for hormone induction. J Biol Chem 2004;279:49857–67.
59. Piper M, Barry G, Harvey TJ, et al. NFIB-mediated repression of the epigenetic factor Ezh2 regulates cortical development. J Neurosci 2014;34:2921–30.
60. Zhao LH, Ba XQ, Wang XG, et al. BAF complex is closely related to and interacts with NF1/CTF and RNA polymerase II in gene transcriptional activation. Acta Biochim Biophys Sin 2005;37:440–6.
61. Liu R, Liu H, Chen X, et al. Regulation of CSF1 promoter by the SWI/SNF-like BAF complex. Cell 2001;106:309–18.
62. Simon JM, Hacker KE, Singh D, et al. Variation in chromatin accessibility in human kidney cancer links H3K36 methyltransferase loss with widespread RNA processing defects. Genome Res 2014;24:241–50.
63. Thurman RE, Rynes E, Humbert R, et al. The accessible chromatin landscape of the human genome. Nature 2012;489:75–82.
64. Stergachis AB, Neph S, Reynolds A, et al. Developmental fate and cellular maturity encoded in human regulatory DNA landscapes. Cell 2013;154:888–903.
65. Semenova EA, Kwon MC, Monkhorst K, et al. Transcription factor NFIB is a driver of small cell lung cancer progression in mice and marks metastatic disease in patients. Cell Rep 2016;16:631–43.
66. Ray BK, Dhar S, Henry C, et al. Epigenetic regulation by Z-DNA silencer function controls cancer-associated ADAM-12 expression in breast cancer: cross-talk between MeCP2 and NF1 transcription factor family. Cancer Res 2013;73:736–44.
67. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998;19:187–91.
68. Nan X, Ng HH, Johnson CA, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998;393:386–9.
69. Harikrishnan KN, Chow MZ, Baker EK, et al. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet 2005;37:254–64.
70. Champ PC, Maurice S, Vargason JM, et al. Distributions of Z-DNA and nuclear factor I in human chromosome 22: a model for coupled transcriptional regulation. Nucleic Acids Res 2004;32:6501–10.
71. Chen H, Toyooka S, Gazdar AF, et al. Epigenetic regulation of a novel tumor suppressor gene (hDAB2IP) in prostate cancer cell lines. J Biol Chem 2003;278:3121–30.
72. Persson M, Andren Y, Mark J, et al. Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009;106:18740–4.
73. D'Alfonso TM, Mosquera JM, MacDonald TY, et al. MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features. Hum Pathol 2014;45:2270–80.
74. Yde CW, Sehested A, Mateu-Regué À, et al. A new NFIA:RAF1 fusion activating the MAPK pathway in pilocytic astrocytoma. Cancer Genet 2016;209:440–4.
75. Micci F, Thorsen J, Panagopoulos I, et al. High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24). Leukemia 2013;27:980–2.
76. Robinson DR, Kalyana-Sundaram S, Wu YM, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 2011;17:1646–51.
77. Buenrostro JD, Wu B, Litzenburger UM, et al. Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 2015;523:486–90.
78. Macosko EZ, Basu A, Satija R, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 2015;161:1202–14.
79. Deng Y, Chan SS, Chang S, Telomere dysfunction and tumour suppression: the senescence connection. Nat Rev Cancer 2008;8:450–8.
80. Robin JD, Ludlow AT, Batten K, et al. Telomere position effect: regulation of gene expression with progressive telomere shortening over long distances. Genes Dev 2014;28:2464–76.
81. Gnyszka A, Jastrzebski Z, Flis S, DNA methyltransferase inhibitors and their emerging role in epigenetic therapy of cancer. Anticancer Res 2013;33:2989–96.
82. West AC, Johnstone RW, New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 2014;124:30–9.
83. Nervi C, De Marinis E, Codacci-Pisanelli G, Epigenetic treatment of solid tumours: a review of clinical trials. Clin Epigenet 2015;7:127.
84. Bhagwat AS, Vakoc CR, Targeting transcription factors in cancer. Trends Cancer 2015;1:53–65.
85. Lee HK, Lee DS, Park JC, Nuclear factor I-C regulates E-cadherin via control of KLF4 in breast cancer. BMC Cancer 2015;15:113.
86. Yao-Borengasser A, Rogers LJ, Edavana VK, et al. Sulfotransferase 1A1 (SULT1A1) gene expression is regulated by members of the NFI transcription factors in human breast cancer cells. BMC Clin Pathol 2014;14:1.
87. Moon HG, Hwang KT, Kim JA, et al. NFIB is a potential target for estrogen receptor-negative breast cancers. Mol Oncol 2011;5:538–44.
88. Eeckhoute J, Carroll JS, Geistlinger TR, et al. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev 2006;20:2513–26.
89. Zhou MJ, Zhou L, Zheng L, et al. miR-365 Promotes cutaneous squamous cell carcinoma (CSCC) through targeting nuclear factor I/B (NFIB). PLoS One 2014;9.
90. Baldwin A, Pirisi L, Creek KE, NFI-Ski interactions mediate transforming growth factor beta modulation of human papillomavirus type 16 early gene expression. J Virol 2004;78:3953–64.
91. Nasri S, More H, Graziano F, et al. A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population. BMC Cancer 2008;8:138.
92. Mao Y, Liu J, Zhang D, et al. MiR-1290 promotes cancer progression by targeting nuclear factor I/X(NFIX) in esophageal squamous cell carcinoma (ESCC). Biomed Pharmacother 2015;76:82–93.
93. Liu C, Duan P, Li B, et al. miR-29a activates Hes1 by targeting Nfia in esophageal carcinoma cell line TE-1. Oncol Lett 2015;9:96–102.
94. Stringer BW, Bunt J, Day BW, et al. Nuclear factor one B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma. Oncotarget 2016;7:29306–29320.
95. Lee JS, Xiao JP, Patel P, et al. A novel tumor-promoting role for nuclear factor IA in glioblastomas is mediated through negative regulation of p53, p21, and PAI1. Neuro-Oncology 2014;16:191–203.
96. Glasgow SM, Laug D, Brawley VS, et al. The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci 2013;33:13560–8.
97. Zhang Q, Cao LY, Cheng SJ, et al. p53-induced microRNA-1246 inhibits the cell growth of human hepatocellular carcinoma cells by targeting NFIB. Oncol Rep 2015;33:1335–41.
98. Becker-Santos DD, Thu KL, English JC, et al. Developmental transcription factor NFIB is a putative target of oncofetal miRNAs and is associated with tumour aggressiveness in lung adenocarcinoma. J Pathol 2016;240:161–72.
99. Mirabello L, Koster R, Moriarity BS, et al. A genome-wide scan identifies variants in NFIB associated with metastasis in patients with osteosarcoma. Cancer Discov 2015;5:920–31.
100. Dooley AL, Winslow MM, Chiang DY, et al. Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 2011;25:1470–5.